Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2
ACS Medicinal Chemistry Letters2012Vol. 3(12), pp. 1091–1096
Citations Over TimeTop 10% of 2012 papers
Sharad K. Verma, Xinrong Tian, Louis V. LaFrance, Céline Duquenne, Dominic Suarez, Kenneth A. Newlander, Stuart P. Romeril, Joelle L. Burgess, Seth W. Grant, James Brackley, Alan P. Graves, D. Scherzer, Art Shu, Christine Thompson, Heidi M. Ott, Glenn S. Van Aller, Carl A. Machutta, Elsie Diaz, Yong Jiang, Neil W. Johnson, Steven D. Knight, Ryan G. Kruger, Michael T. McCabe, Dashyant Dhanak, Peter J. Tummino, Caretha L. Creasy, William H. Miller
Abstract
The histone H3-lysine 27 (H3K27) methyltransferase EZH2 plays a critical role in regulating gene expression, and its aberrant activity is linked to the onset and progression of cancer. As part of a drug discovery program targeting EZH2, we have identified highly potent, selective, SAM-competitive, and cell-active EZH2 inhibitors, including GSK926 (3) and GSK343 (6). These compounds are small molecule chemical tools that would be useful to further explore the biology of EZH2.
Related Papers
- → Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2(2012)375 cited
- → Weaver Syndrome‐Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro(2015)85 cited
- → Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity(2017)35 cited
- → Fine-tuning of lysine side chain modulates the activity of histone lysine methyltransferases(2020)7 cited
- → EZH2 does it(2010)